Chong Kun Dang Pharmaceutical became the first Korean pharmaceutical company to export products to the US market through the obtainment of the U.S. FDA approval.
Chong Kun Dang Pharmaceutical Corp is one of the leading Korean pharmaceutical manufacturers and has a great strength on domestic sales not only with prescription drugs indicated for anti-hypertension, anti-hyperlipidemia and anti-diabetics but also with OTC drugs such a Penzal, Prefemine, Modcol and consumer health such as insecticides, hairdye, etc.
Their high-tech manufacturing facility, Cheon-An plant located in Cheon-An City, Chung Cheong Nam Do has an area of 13,700㎡ and gross floor area of 5,000㎡ .
Here the process of dispensing raw materials, production, packaging and release of finished products is controlled by an automated warehousing system.
Chong Kun Dang was the first in Korea to run its own research institute; it also invested a huge
portion of its resources in nurturing and training research manpower.
Chong Kun Dang Research Institute is characterized by three independent laboratories:
The New Drug Discovery Labs, for identifying innovative drug candidates, The Technology Development Labs, dedicated to generic drugs, APIs, and botanical drugs,
and The Bio Research Labs for developing antibodies, vaccines, and recombinant proteins.
Chong Kun Dang has distinguished achievements in drug development including the following :
Despite its ageing population and growing need for healthcare, South Korea had just 2.6 doctors per 1,000 inhabitants in 2022, one of the lowest numbers among developed nations. To deal…
The latest pharma and healthcare news from APAC, including Celltrion’s plans to sell its Takeda portfolio to CBC; reforms to the South Korean national insurance system that may lead to…
Global medtech giant Medtronic is hoping that its latest acquisition – EOFlow, a South Korean wearable insulin patch maker – will enhance its competitiveness in the global diabetes market. …
A roundup of some of the most important recent stories from the burgeoning South Korean pharma and biotech industry, including a government plan to expand collaboration with the global innovation…
As big pharma continues to sharpen its focus on R&D by outsourcing other elements of the supply chain, including manufacturing, CDMOs have thrived. Samsung Biologics, one of the world’s top…
Korean biotech SK Bioscience, known for bringing forward the first South Korean-developed COVID-19 vaccine, is pursuing its beyond-COVID growth strategy with a new green light for its SKYCellflu vaccine. The…
After launching the first Korean COVID-19 vaccine, SKYCovione, SK Bioscience is preparing for its next big milestone, a US subsidiary, with the appointment of two new executives who are already…
SK Bioscience’s announcement that the first batch of its domestically developed COVID vaccine has been shipped may mark a significant milestone in South Korea’s journey towards greater vaccine self-sufficiency. …
ExoCoBio’s CEO, Byong Seung Cho, went from biotech venture capital to setting up ExoCoBio, a company whose core technology is based on adipose stem-cell derived exosomes for regenerative medicine and…
South Korea has carved a place for itself as a dominant player in the global pharma and med-tech manufacturing industry with national companies Samsung Biologics and Celltrion leading the way.…
After a dynamic two years as CEO of Samsung Biologics, John Rim highlights some of the fundamentals behind the company’s rapid growth as a CDMO, including the creation of huge…
Stephen Yoo highlights the pioneering work that STCube Pharmaceuticals – a US subsidiary of Korean firm STCube – is undertaking in the immuno-oncology field, its three technology platforms, partnership approach,…
See our Cookie Privacy Policy Here
